Related Experiment Video
Updated: May 20, 2026
10:28
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
Oral vasodilators for primary Raynaud's phenomenon.
Marlene Stewart1, Joanne R Morling
1Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. Marlene.Stewart@ed.ac.uk.
The Cochrane Database of Systematic Reviews
|July 13, 2012
Summary
This review found limited evidence for vasodilator drugs in treating primary Raynaud's phenomenon. Most studies had poor quality, showing no significant benefits for common treatments.
Area of Science:
- Vascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Primary Raynaud's phenomenon treatment options are limited, with calcium channel blockers being the primary choice.
- Evidence for alternative pharmacological treatments remains scarce.
- This review is an update of research first published in 2008.
Purpose of the Study:
- To evaluate the efficacy of various vasodilator drugs for symptomatic relief in primary Raynaud's phenomenon.
- To assess the impact of these drugs on symptom frequency, severity, and patient-reported outcomes.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) using oral vasodilator formulations.
- Searched multiple databases and contacted pharmaceutical companies for data.
- Included studies comparing vasodilators to placebo, excluding calcium channel blockers.
Main Results:
- Eight RCTs with 290 participants were analyzed, most of poor methodological quality.
- Enalapril showed a slight increase in attack frequency; buflomedil and moxisylyte had mixed results on attack frequency.
- No significant effects were found for captopril, beraprost, dazoxiben, or ketanserin; beraprost and moxisylyte increased adverse events.
Conclusions:
- Limited data and poor study quality restrict the conclusions that can be drawn.
- Currently, there is insufficient evidence to support the use of these vasodilator drugs for primary Raynaud's phenomenon.
- Further high-quality research is needed to clarify potential treatment benefits.
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...